Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMK34MZ)

• Drug Name: Xilonix Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 3	[1]
Influenza virus infection	1E30-1E32	Phase 3	[2]
Non-small-cell lung cancer	2C25.Y	Phase 2	[3]

• Cross-matching ID: TTD Drug ID: DMK34MZ

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-1 alpha (IL1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MABp1	DM8D13S	Colorectal cancer	2B91.Z	Phase 3	[5]
ABT-981	DM6PTIX	Osteoarthritis	FA00-FA05	Phase 2	[6]
Bermekimab	DM7A592	Hidradenitis suppurativa	ED92.0	Phase 2	[7]
Natrunix	DMBRSWJ	Arthritis	FA20	Phase 2	[8]
IX207-887	DM4TE8R	Rheumatoid arthritis	FA20	Discontinued in Phase 2	[9]
IL1aQb	DMKS4Z9	Arteriosclerosis	BD40	Terminated	[10]
Interleukin-1-alpha - Amgen/Roche	DMB9AIX	Discovery agent	N.A.	Investigative	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-1 alpha (IL1A)	TTPM6HI	IL1A_HUMAN	Modulator	[4]

References

• [1] ClinicalTrials.gov (NCT02138422) A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Xbiotech.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of xbiotech.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs. 2015;7(3):605-19.
• [7] Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol. 2021 Jun;30 Suppl 1:8-17.
• [8] ClinicalTrials.gov (NCT05363917) Phase II Double-Blinded, Placebo-Controlled Randomized Study Examining the Safety and Efficacy of Natrunix Versus Methotrexate (+Folate) for the Treatment of Rheumatoid Arthritis. U.S.National Institutes of Health.
• [9] Inhibition of interleukin-1 release by IX 207-887. Agents Actions. 1990 Jun;30(3-4):350-62.
• [10] Cytos Biotechnology AG - Product Pipeline Review - 2013. Global Markets Direct. Dec 2013.
• [11] Identification of regions in interleukin-1 alpha important for activity. J Biol Chem. 1993 Oct 15;268(29):22105-11.